偉思醫療(688580.SH):海外業務仍還在孵化中 暫時不會對公司業績造成很大影響
格隆匯7月25日丨偉思醫療(688580.SH)近日在接待機構投資者調研時表示,海外市場是一個更為廣闊的市場,公司對海外市場擴展長期保持積極態度,公司在2023年獲得了塑形磁、盆底功能磁產品FDA認證,也陸續開始參與到一些國外的展會中。目前公司正加快海外市場註冊取證、合規准入工作,同時開始搭建國際銷售網絡,促進企業的國際化發展。但短期來看,海外業務仍還在孵化中,暫時不會對公司業績造成很大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.